Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Five epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are available for first-line treatment of non-small-cell lung cancer (NSCLC) in Japan.
• Patient populations with EGFR-mutated NSCLC often receive first-line EGFR TKIs.
• Comparative efficacy data for these agents in the Japanese population is limited.

Purpose of the Study:

• To compare the relative efficacy of first-line EGFR TKIs in Japanese patients with NSCLC.
• To evaluate progression-free survival (PFS) outcomes for various EGFR TKIs.
• To identify optimal first-line treatment strategies for EGFR-mutated NSCLC in Japan.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) investigating first-line EGFR TKIs.
• Bayesian network meta-analysis to compare efficacy outcomes.
• Assessment of progression-free survival (PFS) as the primary endpoint.

Main Results:

• Seven RCTs were included in the network meta-analysis.
• Dacomitinib demonstrated a trend toward improved PFS compared to all other evaluated EGFR TKIs.
• No other significant differences in PFS were highlighted between comparators.

Conclusions:

• Dacomitinib showed a trend towards superior PFS in the first-line treatment of Japanese patients with EGFR-mutated NSCLC.
• Dacomitinib should be considered a potential standard first-line therapy option.
• Further research may be warranted to confirm these findings in the Japanese population.